Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Politics

Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

by admin March 26, 2025
March 26, 2025
Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

The Senate Committee on Finance voted along party lines Tuesday afternoon to advance Dr. Mehmet Oz, President Donald Trump’s pick to lead the Centers for Medicare and Medicaid Services, to a full confirmation vote. 

The party-line vote, which saw 14 GOP senators vote in favor of Oz’s nomination and 13 Democrats vote against it, follows two hearings by the Senate Finance Committee that probed Oz over his plans for the federal healthcare programs, his views on abortion, potential conflicts of interest in the healthcare industry and more.

‘Dr. Oz has years of experience as an acclaimed physician and public health advocate. His background makes him uniquely qualified for this role, and there is no doubt that he will work tirelessly to deliver much-needed change at CMS,’ Sen. Mike Crapo, R-Idaho, the chairman of the committee, said Tuesday. 

Oz graduated from Harvard University and received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime TV and 13 seasons of ‘The Dr Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He ultimately lost to John Fetterman, then the state’s lieutenant governor. 

If confirmed by the full Senate, Oz would be in charge of nearly $1.5 trillion in federal healthcare spending. Medicare, a federal healthcare program for seniors aged 65 and up, currently provides coverage for about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, which assists people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov.

Oz’s leadership would direct decisions related to how the government covers procedures, hospital stays and medication within the federal healthcare programs, as well as the reimbursement rates at which healthcare providers get paid for their services.

Earlier this month, Trump’s pick to lead the NIH and FDA, Dr. Jay Bhattacharya and Dr. Marty Makary, respectively, were also approved in committee and are awaiting full confirmation votes in the Senate scheduled for later Tuesday. It is unclear when Oz’s full Senate vote will take place.

Around the same time that Bhattacharya and Makary won committee approval, Trump withdrew his nomination of former Florida Rep. David Weldon to run the CDC, over fears he did not have the GOP support to clear full confirmation. On Monday, the Trump administration named Susan Monarez, acting director of the CDC, as its new nominee.

This post appeared first on FOX NEWS

previous post
Trump FDA pick clears last hurdle after flipping vaccine question on Dem in confirmation hearing
next post
CIA Director Ratcliffe hits back on Dem senator’s group chat allegations: ‘I didn’t say any of those things’

Related Posts

Senate forces rare weekend vote to push through...

January 26, 2025

Musk was never briefed on China war plans...

March 22, 2025

Waltz tells Iran to give up nuclear program...

March 24, 2025

JONATHAN TURLEY: Biden not the only loser revealed...

May 18, 2025

Trump says he has instructed US Treasury to...

February 10, 2025

Kevin Hassett doubles down on Trump tariffs, says...

April 7, 2025

Hamas to release 3 more hostages, including US...

February 1, 2025

First-term House Dem attacks White House spox Karoline...

January 30, 2025

Trump tax cuts survive key House hurdle as...

April 10, 2025

Denmark in Trump’s crosshairs as Vance makes ambitious...

March 29, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved